ARS Investment Partners’s CareDx CDNA Stock Holding History

ARS Investment Partners’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12M	Sell	74,235 -3,000	-4%	-$65.3K	0.09%	80
2026 Q1	$1.34M	Sell	77,235 -17,104	-18%	-$324K	0.07%	88
2025 Q4	$1.78M	Sell	94,339 -11,716	-11%	-$196K	0.1%	79
2025 Q3	$1.54M	Buy	106,055 +10,170	+11%	+$145K	0.1%	82
2025 Q2	$1.87M	Sell	95,885 -6,083	-6%	-$108K	0.14%	73
2025 Q1	$2.18M	Hold	101,968	–	–	0.2%	61
2024 Q4	$2.18M	Buy	101,968 +6,083	+6%	+$148K	0.2%	61
2024 Q3	$2.99M	Buy	95,885 +14,450	+18%	+$360K	0.27%	53
2024 Q2	$1.26M	Sell	81,435 -52,675	-39%	-$637K	0.12%	69
2024 Q1	$1.42M	Sell	134,110 -17,400	-11%	-$174K	0.14%	70
2023 Q4	$1.82M	Sell	151,510 -220	-0.1%	-$1.8K	0.2%	60
2023 Q3	$1.06M	Hold	151,730	–	–	0.13%	74
2023 Q2	$1.29M	Hold	151,730	–	–	0.15%	72
2023 Q1	$1.39M	Buy	+151,730	New	+$1.94M	0.17%	72
2019 Q3	–	Sell	-9,800	Closed	-$353K	–	112
2019 Q2	$353K	Buy	+9,800	New	+$314K	0.06%	110

Other funds holding CDNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ARS Investment Partners's CDNA Position: Q2 2026 in Review

ARS Investment Partners reduced its CareDx (CDNA) stake by 3.9% in Q2 2026, selling an estimated $65.3K and leaving 74,235 shares worth $2.12M. The position accounts for 0.09% of the portfolio, ranked #80.

ARS Investment Partners first reported a position in CDNA in Q2 2019 and has held it in 15 quarters since. The position peaked at $2.99M in Q3 2024. 227 funds tracked by Wall St. Rank hold CDNA as of Q2 2026.

ARS Investment Partners held 74,235 shares of CareDx worth $2.12M as of Q2 2026.
ARS Investment Partners sold 3,000 CareDx shares in Q2 2026, an estimated $65.3K.
CareDx made up 0.09% of ARS Investment Partners's portfolio in Q2 2026, its #80 holding.
ARS Investment Partners first reported a position in CareDx in Q2 2019 and has held it in 15 quarters since.
ARS Investment Partners's CareDx position peaked at $2.99M in Q3 2024.
227 funds tracked by Wall St. Rank held CareDx as of Q2 2026.

Based on ARS Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.